This is a prospective, single-arm, single-center, explorative clinical trial to evaluate the
effect of Rituximab on disease progression in subjects with SLE-PAH receiving concurrent
stable-dose standard medical therapy. The study will focus on assessment of clinical response
and safety measures longitudinally. In addition, the biomarker of treatment efficacy with
Rituximab and pathogenic autoantibody response in this disease will be investigated.